ANIK Valuation

Anika Therapeutics Inc

Add to Watchlist

Advanced Chart

13.640

+0.040(+0.290%)

Overview
Forecast
Valuation

ANIK Relative Valuation

ANIK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ANIK is overvalued; if below, it's undervalued.

Historical Valuation

Anika Therapeutics Inc (ANIK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.71 is considered Undervalued compared with the five-year average of 2.79. The fair price of Anika Therapeutics Inc (ANIK) is between 18.56 to 29.24 according to relative valuation methord. Compared to the current price of 13.64 USD , Anika Therapeutics Inc is Undervalued By 26.53%.

Relative Value

Fair Zone

18.56-29.24

Current Price：13.64

26.53%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.28

P/B

Median3y

1.44

Median5y

1.62

-1.21

FCF Yield

Median3y

-1.05

Median5y

0.38

Competitors Valuation Multiple

The average P/S ratio for ANIK's competitors is 3.34, providing a benchmark for relative valuation. Anika Therapeutics Inc Corp (ANIK) exhibits a P/S ratio of 1.71, which is -48.66% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

ANIK.O

Anika Therapeutics Inc

1.71

Average P/S: 3.34

193.36M